Evidence map›Paper›PMID 29067350›Full record

ReviewAlzheimer's & dementia (New York, N. Y.)2017

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms.

Krista L Lanctôt, Joan Amatniek, Sonia Ancoli-Israel, Steven E Arnold, Clive Ballard, Jiska Cohen-Mansfield, Zahinoor Ismail, Constantine Lyketsos, David S Miller, Erik Musiek and 10 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia (New York, N. Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 5 pooled it
24.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

169 citing papers in PubMed, 5 syntheses or guidelines pooled it, 382 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Neuropsychiatric symptoms in Alzheimer's disease: Past, present, and future.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  20. Review

109 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 4 countries.

Krista L LanctôtHurvitz Brain Sciences Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Canada.
Joan AmatniekOtsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
Sonia Ancoli-IsraelDepartment of Psychiatry, University of California, San Diego, CA, USA.
Steven E ArnoldInterdisciplinary Brain Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
Clive BallardInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Jiska Cohen-MansfieldDepartment of Health Promotion, School of Public Health, Sackler Faculty of Medicine and Minerva Center for the Interdisciplinary Study of End of Life, Tel Aviv University, Tel Aviv, Israel.
Zahinoor IsmailDepartment of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Constantine LyketsosDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine Institutes, Baltimore, MD, USA.
David S MillerBracket Global, Wayne, PA, USA.
Erik MusiekDepartment of Neurology, Hope Center for Neurological Disorders, and Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Ricardo S OsorioCenter for Brain Health, NYU Langone Medical Center, New York, NY, USA.
Paul B RosenbergDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew SatlinEisai, Inc., Woodcliff Lake, NJ, USA.
David SteffensDepartment of Psychiatry, University of Connecticut School of Medicine, Farmington, CT, USA.
Pierre TariotBanner Alzheimer's Institute, Phoenix, AZ, USA.
Lisa J BainElverson, PA, USA.
Maria C CarrilloAlzheimer's Association, Chicago, IL, USA.
James A HendrixAlzheimer's Association, Chicago, IL, USA.
Heidi JurgensAlzheimer's Association, Chicago, IL, USA.
Brendon BootDepartment of Neurology, Brigham and Women's Hospital, Harvard University School of Medicine, Boston, MA, USA.
Alzheimer's Association · USJohns Hopkins Medicine · USBanner Alzheimer’s InstituteEisai (United States) · USHope Center for Neurological Disorders · USKing's College London · GBMassachusetts General Hospital · USNYU Langone Health · USOtsuka (United States) · USSunnybrook Health Science Centre · CATel Aviv University · ILUniversity of Calgary · CAUniversity of California, San Diego · USUniversity of Connecticut · USVoyager Therapeutics (United States) · US

Funding

'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI HUGANIR, RICHARD L · 1985 to 2019
$37.6M
PSYCHOSOCIAL COREP30AG008051 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SHAO, YONGZHAO · 1990 to 2019
$36.1M
Brain Sleep Clearance of Amyloid-Beta Peptides Study (Brain SCRAPS)R21AG049348 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OSORIO, RICARDO S · 2015 to 2016
$454k
NIA NIH HHS P30 AG008051NIA NIH HHS P50 AG005146NIA NIH HHS R21 AG049348
6 · The paper itself

Abstract

Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.

Indexed as

AgitationAlzheimer's diseaseApathyDelusionsDepressionHallucinationsNeuropsychiatric symptomsSleep disturbanceTrial design

Identifiers

PMID29067350
PMCPMC5651439
OpenAlexW2743290174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.